# A Study of MET233 in Individuals With Obesity or Overweight

> **NCT07022977** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Metsera, a wholly owned subsidiary of Pfizer** · enrollment: 120 (estimated)

## Conditions studied

- Obesity and Overweight

## Interventions

- **BIOLOGICAL:** MET233
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07022977
- **Lead sponsor:** Metsera, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-04-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07022977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07022977, "A Study of MET233 in Individuals With Obesity or Overweight". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07022977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*